Shares of Thryv Holdings, Inc. (THRY) have gained 16% over the past four weeks to close the last trading session at $13.8, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $21.4 indicates a potential upside of 55.1%.The average comprises five short-term price targets ranging from a low of $16.00 to a high of $26.00, with a standard deviation of $4.1. While the lowest estimate ind ...

Group 1 - El Pollo Loco Holdings (LOCO) shares have increased by 1% over the past four weeks, closing at $10.69, with a mean price target of $13.75 indicating a potential upside of 28.6% [1] - The mean estimate consists of four short-term price targets with a standard deviation of $2.99, where the lowest estimate is $11.00 (2.9% increase) and the highest is $18.00 (68.4% increase) [2] - Analysts show strong agreement on LOCO's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for LOCO has risen by 2.7% over the past month, with two estimates increasing and no negative revisions [12] - LOCO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide guidance on the direction of price movement [14]

Core Viewpoint - Enerflex (EFXT) has shown a significant price increase of 13.9% over the past four weeks, with a mean price target of $11.81 indicating a potential upside of 28.8% from its current price of $9.17 [1] Price Targets and Analyst Consensus - The average price target consists of eight estimates ranging from a low of $9.25 to a high of $13.81, with a standard deviation of $1.58, indicating variability among analysts [2] - The lowest estimate suggests a modest increase of 0.9%, while the highest estimate indicates a substantial upside of 50.6% [2] - A low standard deviation signifies strong agreement among analysts regarding the stock's price movement direction, although it does not guarantee reaching the average target [9] Earnings Estimates and Analyst Optimism - Analysts exhibit strong agreement in revising earnings estimates higher for EFXT, which correlates with potential stock price increases [11] - Over the past 30 days, two earnings estimates have increased while one has decreased, leading to a 37.8% rise in the Zacks Consensus Estimate for the current year [12] - EFXT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a solid potential upside [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research indicates they often do not accurately predict stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Group 1 - Soleno Therapeutics, Inc. (SLNO) shares have increased by 1% over the past four weeks, closing at $82.35, with a mean price target of $117.88 indicating a potential upside of 43.2% [1] - The mean estimate consists of eight short-term price targets with a standard deviation of $13.62, where the lowest estimate is $100.00 (21.4% increase) and the highest is $145.00 (76.1% increase) [2] - Analysts show a strong consensus that SLNO will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for SLNO's current year earnings has risen by 56.7% over the past month, with five estimates increasing and no negative revisions [12] - SLNO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for near-term upside [13] - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [14]

Core Viewpoint - Sky Harbour Group Corporation (SKYH) shows potential for significant upside, with a mean price target of $17.92 indicating a 73% increase from its current price of $10.36 [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $4.8, suggesting variability in analyst predictions [2] - The lowest estimate of $14.00 indicates a 35.1% increase, while the highest estimate of $25.00 suggests a potential surge of 141.3% [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about SKYH's earnings prospects, with a positive trend in earnings estimate revisions [11] - Over the last 30 days, one estimate has increased, leading to a 9.8% rise in the Zacks Consensus Estimate [12] - SKYH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as analysts' ability to set unbiased targets has been questioned [3][7] - Price targets should be treated with skepticism, as they can mislead investors [10]

Group 1 - Rapt Therapeutics (RAPT) shares have increased by 34.2% over the past four weeks, closing at $10.8, with a mean price target of $24 indicating a potential upside of 122.2% [1] - The average price targets range from a low of $14.00 to a high of $31.00, with a standard deviation of $8.89, suggesting a variability in estimates; the lowest estimate indicates a 29.6% increase, while the highest points to a 187% upside [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, as the Zacks Consensus Estimate for the current year has increased by 33.4% [4][12] Group 2 - RAPT currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13] - While price targets can be misleading, the direction implied by the consensus price target suggests a positive outlook for RAPT's stock [10][14]

Core Viewpoint - Crescent Energy (CRGY) has seen a 3.7% increase in share price over the past four weeks, closing at $8.92, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $14.92, representing a 67.3% upside [1] Price Targets - The average of 12 short-term price targets ranges from a low of $10.00 to a high of $20.00, with a standard deviation of $2.75, indicating variability among estimates [2] - The lowest estimate suggests a 12.1% increase from the current price, while the highest estimate indicates a 124.2% upside [2] Analyst Consensus - There is strong agreement among analysts regarding CRGY's ability to report better earnings than previously predicted, which supports the view of potential upside [4] - The Zacks Consensus Estimate for the current year has increased by 13.5% over the past month, with three estimates rising and one falling [12] Zacks Rank - CRGY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside [13] Caution on Price Targets - While price targets are a common metric for investors, relying solely on them for investment decisions may not be wise due to historical inaccuracies in predicting stock price movements [3][7][10]

Core Viewpoint - ACI Worldwide (ACIW) shares have increased by 2.1% recently, with a mean price target of $64.6 suggesting a potential upside of 41.4% from the current price of $45.7 [1] Price Targets and Analyst Consensus - The average price target for ACIW ranges from a low of $60.00 to a high of $77.00, with a standard deviation of $7.4, indicating a relatively tight clustering of estimates [2] - The lowest estimate suggests a 31.3% increase, while the highest indicates a 68.5% upside [2] - Analysts' price targets can be misleading, as they often set overly optimistic targets due to business incentives [8][10] Earnings Estimates and Potential Upside - There is strong agreement among analysts regarding ACIW's ability to report better earnings, which supports the expectation of an upside [4][11] - The Zacks Consensus Estimate for the current year has increased by 0.1% over the past month, with no negative revisions [12] - ACIW holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While consensus price targets may not be reliable for predicting the extent of ACIW's gains, they can provide a useful guide for the direction of price movement [14]

Core Viewpoint - Immunovant, Inc. (IMVT) shows significant upside potential with a mean price target of $41.57, indicating a 137.7% increase from the current price of $17.49 [1] Price Targets and Analyst Consensus - The average of 14 short-term price targets ranges from a low of $17.00 to a high of $61.00, with a standard deviation of $15.37, suggesting variability in analyst estimates [2] - The lowest estimate indicates a potential decline of 2.8%, while the highest suggests a 248.8% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about IMVT's earnings prospects, with a positive trend in earnings estimate revisions [11] - Over the last 30 days, two estimates have been revised higher, leading to a 3.4% increase in the Zacks Consensus Estimate [12] - IMVT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' ability to set accurate targets has been questioned [3][7] - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates [8] - While price targets should not be ignored, they should be approached with skepticism and not be the sole basis for investment decisions [10]

Core Viewpoint - Zevra Therapeutics (ZVRA) has shown a significant price increase of 40.2% over the past four weeks, with a mean price target of $23.86 indicating an upside potential of 86.6% from the current price of $12.79 [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $3.39, where the lowest estimate is $19.00 (48.6% increase) and the highest is $29.00 (126.7% increase) [2] - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding ZVRA's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates with potential stock price movements [11] - Over the last 30 days, two earnings estimates for ZVRA have increased, leading to a Zacks Consensus Estimate increase of 145.2% [12] Zacks Rank and Investment Potential - ZVRA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While consensus price targets may not be entirely reliable, the direction they imply appears to be a useful guide for potential price movements [14]